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Abstract The p.Arg420His allelic form of spinocerebellar
ataxia type 13 has been reported in a large Filipino kindred,
as well as three European index cases, one with an affected
offspring. Haplotype analysis has confirmed independent mu-
tational events. All individuals share adult-onset, predominant-
ly cerebellar signs and a slowly progressive course. However, a
comprehensive phenotypic description has yet to be published
on SCA13p.Arg420His. In this study, we present the results of a
detailed neurological clinical and diagnostic testing on 21
mutation-positivemembers of a four-generation Filipino family
to further define this disease, aiding diagnosis and prognosis.
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Introduction
Spinocerebellar ataxia type 13 (SCA13) is an autosomal dom-
inantly inherited disorder caused by mutations in KCNC3 cod-
ing for the Kv3.3 voltage-gated potassium channel [1]. Of the
three SCA13-causative mutations described, the p.Phe448Lys
and p.Arg423His mutant alleles result in developmental pheno-
types with delayed motor milestones, mental retardation, and
epilepsy [2, 3] whereas the p.Arg420His mutation effects a
neurodegenerative phenotype clinically resembling other SCA
subtypes [1, 2]. In vitro experimental systems have shown that
each mutation possesses distinct biophysical properties. The
electrophysiological profiles of the p.Arg420His allele are con-
sistent with a null mutation. Moreover, co-expression with a
wild-type allele demonstrates a dominant negative effect that is
specific to Shaw subtype voltage-gated potassium channels. In
contrast, the p.Phe448Lys and p.Arg423His mutations alter the
gating, conductance, and closing properties of the channel [1, 3].
There has been increasing identification of SCA subtypes
in the last several years. Many of the common SCAs are
related to unstable repeat expansion mutations though re-
cently an increasing number of point mutations have been
linked to similar phenotypes. The phenotypic overlap among
different genotypes and phenotypic heterogeneity related to
specific genotypes oftentimes prevents facile identification
of the underlying mutation based on clinical features alone
[4–6]. Common practice involves obtaining panels of diag-
nostic DNA tests covering all known ataxias at considerable
expense. Accurate genotypic diagnosis brings closure to the
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evaluative process for patients and their families, permits
improved genetic counseling, and facilitates participation in
targeted research studies and clinical trials. Further, specific
and well-characterized phenotypic features may aid the cli-
nician in prioritizing the mutation analysis.
Here, we report detailed phenotypic features in a large
Filipino kindred harboring the SCA13p.Arg420His mutation,
extend the limited clinical observations reported with the
original linkage studies, and provide the most comprehensive
description of this SCA13 allelic form.
Methods
Forty-one members of a four-generation Filipino kindred seg-
regating the KCNC3p.Arg420His allele were comprehensively
examined, and blood samples were collected for mutation
detection (Fig. 1). Data obtained included detailed medical
and neurological histories: full neurological examination to
obtain information on their oculomotor, bulbar, cerebellar,
upper motor neuron, lower motor neuron, extrapyramidal and
peripheral nervous systems, Montreal Cognitive Assessment
(MoCA-P, Philippine version 7.1, 2010 administered by a
trained local neuropsychologist), Scale for Assessment and
Rating of Ataxia (SARA) score [7], “functional stage” indicat-
ing mobility status [8] (grade 0 being asymptomatic and grade
6 being bedbound and needing full help with activities of daily
living), activities of daily living scale (Unified Huntington’s
Disease Rating Scale (UHDRS IV)), and EQ-5D self-assessed
quality of life scale. All data were obtained prior to mutation
testing. Three affected members had nerve conduction studies
performed. One underwent a 1-h sleep/awake EEG. MR
imaging of the brain was obtained in five individuals, II-1, II-
14, III-1, IV-1, and III-3. Serial scans for a mother–daughter
pair (II-1/III-2) with a 5-year interval are included for longitu-
dinal comparison. University of Florida Institutional Review
Board approval for this study and signed informed consents for
all patients have been retained. The original report of this
family was limited to 11 affected individuals (I-1, II-1, II-4,
II-5, II-6, II-7, II-10, II-14, III-2, III-3, and III-4) examined
only for cerebellar, gait, and motor system abnormalities [2].
Results
Of the 41 individuals studied, 21 (M/F 8:13) were found to
harbor the p.Arg420His (c.1259G>A) mutation. Nine
mutation-positive individuals (M/F 3:6) had not yet devel-
oped clinical symptoms. Mean age at onset among the 12
symptomatic individuals was 37.3 years (range 25 to 60)
with a standard deviation (SD) of 12.7 years, and the mean
age at examination was 54.7±16 (SD)years (range 32 to 82).
Mean duration of disease at examination was 17.6±14.7
(SD)years (range 1 to 48). All symptomatic subjects dem-
onstrated gait and limb ataxia. In two, cerebellar signs were
limited to gait and lower limbs. Dysarthria was found in
10/12. As previously reported, none of the individuals had
cerebellar oculomotor disturbance including nystagmus, ab-
normal pursuit, or saccadic dysmetria [9]. Ocular movements
were full, saccadic speed was normal, and there was no ptosis.
Three patients, none with a weak cough, reported dysphagia.
Decreased vibration sense involving toes occurred in 6/12
(age at examination was 53 to 82 years with diabetes in two)
though no additional sensory abnormalities were observed.
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Fig. 1 Pedigree showing an extended SCA13 Filipino family. Filled
black symbols are clinically affected individuals with known c.1259G>A
genotype. Gray symbols represent asymptomatic examined individ-
uals with known genotype.White insets indicate two wild-type alleles.
Of the remaining 12 at-risk individuals, nine are c.1259G>A hetero-
zygotes and three are wild type. They are not identified for privacy
concerns. Bold numbers indicate the ages at examination and disease
onset
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Brisk deep tendon reflexes without spasticity were found in
five patients, being confined to the lower limbs in two and to
the upper limbs in two. One individual (diabetic) had absent
deep tendon reflexes. None had extensor plantar reflex,
chorea, dystonia, tremor, or other extrapyramidal signs. Three
individuals reported mild bladder control issues, and one had
nocturnal enuresis. Two persons reported occasional sudden
trunk movements consistent with myoclonic jerks though no
myoclonus was observed during examination. None reported
histories of seizures or episodic ataxia (Table 1).
The mean SARA score at examination was 12.8±8.7 (SD)
(range 1 to 32.5), and the mean functional stage was 2.9±1
(SD) (range 2–5). The annualized SARA score increase, as a
function of disease duration, was 0.73 per year. Three persons
used canes, one at the onset of disease at age 60 and the others
after 13 and 20 years of disease onset. One person started
using a walker after 28 years of disease progression. A
73-year-old woman with a 48-year disease duration was
wheelchair-bound. The remaining seven patients continued
to ambulate unassisted, including three subjects with a disease
duration of 10 to 25 years. The mean score on the EQ-5D
visual analog scale was 65.5±13.6 (SD) (100 being the best
possible and 0 being the worst possible self-perceived health),
and the mean UHDRS IV functional score was 18.5±4.5 (SD)
(25 being the best and 0 being the worst functional capacity).
The MoCA-P revealed 14 of 21 (67 %) scores in the abnor-
mal range, which were less than 26 (23±3.9 SD, range 15–29).
Themost common deficit was delayed recall in ten subjects and
abnormal verbal fluency in eight. Visuospatial skills (clock or
cube drawing) were also impaired in eight. However, these
results must be interpreted with caution as (1) there was little
correlation between MoCA-P severity and disease duration
(Pearson r=−0.38) or SARA score (Pearson r=−0.37), (2)
seven (33 %) symptomatically affected individuals scored in a
normal range, and (3) 6 of 18 unaffected noncarriers (33 %)
who were tested also scored less than 26 sharing delayed recall
as the most common deficit (26±2.3 SD, range 21–29).
MR scans of the brain in four test subjects revealed isolated
cerebellar atrophy (Fig. 2). In two individuals in which serial
scans with a 5-year interval was available, no significant
progression of atrophy could be appreciated in spite of clear
progression of SARA disease severity (Fig. 2b, e, c, f). Sensory
and motor nerve conduction studies were performed on three
symptomatic individuals and revealed no pathological findings
to indicate a peripheral neuropathy. One-hour sleep/awake
EEG in a symptomatic individual (SARA 10.5) was normal
without evidence for epileptic discharges, focality, slowing, or
other pathologic patterns.
The mean age at examination of the nine mutation-
positive asymptomatic subjects was 24±7.3 (SD)years.
Among these subjects, four had brisk deep tendon reflexes,
one of whom also had mild lower extremity spasticity and a
slight tremor. A fifth patient demonstrated a minimally ab-
normal heel to shin test. In all other respects, their neurolog-
ical examination was normal. Seven of the nine mutation-
positive asymptomatic subjects had a SARA score of 0 and
two obtained scores of 1 and 1.5 but self-described as
asymptomatic. Mean EQ-5D VAS score was 80.1±16.4
(SD), and the UHDRS score was 23.5±2.5 (SD).
Discussion
An adult-onset, slowly progressive ataxic syndrome character-
izes the phenotype of SCA13 related to the KCNC3p.Arg420His
mutation with a widely ranging age at onset. The clinical signs
were primarily purely cerebellar, though no oculomotor pathol-
ogies related to cerebellar degeneration were detected. Brisk
deep tendon reflexes were found in less than half of the subjects
without associated marked spasticity or upper motor neuron
signs suggestive of upper motor neuron dysfunction. Half of the
subjects had diminished vibration sense in the toes though two
of them were diabetic and the others were over 50 years of age,
confounding the determination of mutation causality. No evi-
dence for extrapyramidal or anterior horn cell involvement was
found. Nerve conduction studies performed on three subjects
were entirely normal with no evidence for peripheral neuropa-
thy. None of the individuals had seizures or episodic symptoms.
Though limited descriptions of SCA13p.Arg420His have
been published previously, this report provides an in-depth
Table 1 Summary of pertinent clinical features among 12 symptomatic
subjects with SCA13R420H
Clinical characteristic Total
Age at onset 37.25±12.7 (range 25–45)years
Male/female (complete pedigree) 10:14
Dysarthria 10/12 (83.3)
Dysphagia 3/12 (25)
Gait ataxia 12/12 (100)
Lower limb ataxia 12/12 (100)
Upper limb ataxia 10/12 (83.3)
Atrophy/weakness 0/12 (0)
Spasticity 1/12 (8.3)
Brisk deep tendon reflexes 5/12 (41.7)
Electrophysiological signs 0/12 (0)
Vibration sensory loss (toes)* 6/12 (50)
Bladder dysfunction 3/12 (25)
Epilepsy/seizures 0/12 (0)
History of myoclonic jerks 2/12 (16.7)
Episodic ataxia features 0/12 (0)
Impaired cognition (MoCA-P)** 14/21 (67)
Numbers within parenthesis are percentages
*Age at exam 53-82 years; 2 with diabetes
**All mutation+ individuals included. See text for details
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phenotypic characterization of the largest sample group to
date including cognitive assessment, formal ataxia scale
ratings, functional staging, and self-assessed quality of life
indicators in presymptomatic, early, middle-, and late-stage
patients. This report is limited in that it describes these
features in a single kindred, though strengthened in that it
includes two pedigree branches and four generations of
subjects. Moreover, it provides an important foundation on
which the natural history of SCA13p.Arg420His may be char-
acterized as it includes examination of presymptomatic pa-
tients as well as those with SARA severity scales ranging
from 1 to 32.5, functional staging of 0.5 to 5, and disease
duration of 1 to 48 years.
Other reports of this SCA13 allele include four individuals
from three different lineages, all discovered by large-scale
DNA sequencing from unknown ataxia repositories [3]. One
individual was described similarly to the current cohort with a
disease duration of approximately 20 years at age 43, cerebel-
lar signs, ataxic gait, and clear progression of symptoms. A
small kindred, one aged 66 years with onset at 42 years, and
their offspring with a 3-year duration at age 31 years also
shared cerebellar signs, gait ataxia, and disease progression
but were also observed to have pyramidal signs and, in the
younger subject, a seizure disorder [10]. This observation
potentially extends the phenotype to include epilepsy, which
has been described in the p.Arg423His allelic form of SCA13
[11]. The final patient, aged 57 years with 6 years of symp-
toms, shared cerebellar and pyramidal signs and gait ataxia.
No follow-up was available to assess for disease progression.
Though the number of affected symptomatic individuals in the
pedigree is too small to perform definitive studies on genetic
modifiers of SCA13p.Arg420His, the number of at-risk individ-
uals in this family, as well as the potential discovery of
additional pedigrees, may provide the opportunity for this type
of analysis in the future.
SCA13p.Arg420His is slowly progressive. The annual in-
crease in SARA score based on this cross-sectional exami-
nation was much slower than for other SCAs associated with
extracerebellar signs such as SCAs 1, 2, and 3 [12]. Only
three individuals used a cane, and only one was wheelchair-
bound despite mean disease duration of 17.6 years. The
minimal decrease in the mean UHDRS IV functional score
reinforces the slow progression.
Contrary to the initial impression that this mutation is not
associated with cognitive impairment, we found evidence for
mild abnormalities in a number of affected individuals. Sev-
en of 12 subjects scored in the abnormal range with deficits
in delayed recall, verbal fluency, and visuospatial tasks.
The mutation-positive but asymptomatic subjects gener-
ally had normal examinations excepting brisk tendon re-
flexes in four. However, a slight tremor, mild heel-to-shin
ataxia, and minimal spastic catches were also observed.
Additionally, imaging evidence suggests that cerebellar
atrophy may significantly precede overt clinical symptom-
atology. Thus, though referencing SCA13p.Arg420His as an
adult-onset, slowly progressive neurodegenerative pheno-
type is clinically accurate, it may underestimate the actual
onset of disease pathology. The evolution of ataxic features
a b c
d e f
Fig. 2 MR T1 midline sagittal
and T2 axial sequences (inset)
suggest progressive cerebellar
atrophy with disease duration
(dd) and SARA severity (ss) (a
disease duration 5 years, SARA
8.5; d disease duration 25 years,
SARA 11). Panels b and e
(daughter) and c and f (mother)
are repeated studies with a 5-year
interval between initial and
subsequent examination and
imaging (a, b 33/38 years; c, d
68/73 years). There is little
change in the degree of
cerebellar vermian atrophy over
5 years though progression of
disease was evident in an
increased SARA from 2 to 10.5
(b, e) and from 27 to 32.5 (c, f).
The brain stem and pons remain
intact in spite of a 48-year
disease duration (f)
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and when these subjects become frankly symptomatic re-
mains to be determined.
Summary
An autosomal dominant ataxia with isolated cerebellar signs,
slow progression, mild cognitive impairment, and absence of
cerebellar oculomotor signs may suggest the p.Arg420His
allelic form of SCA13. Isolated cerebellar atrophy on MRI
with little change over many years would further strengthen
this conclusion.
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